Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma

Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01018329

Enrollment

Registered

2009-11-23

Start date

2009-07-31

Completion date

2012-12-31

Last updated

2012-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor

Keywords

Adult Brain Tumor

Brief summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying magnetic resonance imaging in response to radiation therapy in patients with high grade glioma.

Detailed description

Detailed DescriptionOBJECTIVES: I. To develop a multimodality statistical model to act as a surrogate marker scheme of early changes in high grade glioma patients undergoing radiation therapy, using conventional MRI, MR diffusion tensor imaging, perfusion, permeability, and spectroscopic imaging while incorporating the radiation dose calculations delivered locally and the results of a clinical questionnaire into the model. II. To assess treatment response to tumor and normal tissue changes. OUTLINE: Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6, and then 4-6 weeks after completion of radiation therapy.

Interventions

PROCEDUREDiffusion-weighted magnetic resonance imaging

PROCEDUREMagnetic Resonance Imaging

PROCEDUREDiffusion Tensor Imaging

PROCEDUREMagnetic Resonance Spectroscopic Imaging

PROCEDUREDynamic Contract-Enhanced magnetic resonance imaging

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients being treated for diagnosed with high grade glioma (WHO grade III or IV) at the University of Pennsylvania Medical Center who will be undergoing radiation therapy to the brain * Patient or legal representative able to provide written informed consent * Adult males and nonpregnant females

Exclusion criteria

* Vulnerable populations as specified (including pregnant patients, prisoners, patients with pacemakers or metallic implants) * Patients with renal failure * Patients with any condition considered a contraindication to MRI

Design outcomes

Primary

Measure	Time frame
Early brain tumor response	—

Secondary

Measure	Time frame
Early therapeutic-induced changes in normal surrounding brain	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026